Structure Therapeutics Inc.
NASDAQ Global MarketTotal Valuation
Structure Therapeutics Inc. carries a market capitalization of 1.27B, placing it among publicly traded companies globally. Its enterprise value stands at 10.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.27B |
| Enterprise Value | 10.11B |
Share Statistics
Structure Therapeutics Inc. currently has 213.21M shares outstanding.
| Shares Outstanding | 213.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 8.45 |
| P/TBV Ratio | 8.45 |
| P/FCF Ratio | -17.04 |
| P/OCF Ratio | -16.71 |
Financial Position
Structure Therapeutics Inc. maintains a current ratio of 20.75, meaning it holds 20.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 20.75 |
| Quick Ratio | 20.31 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -20.21 |
| Return on Assets (ROA) | -19.17 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Structure Therapeutics Inc. has paid 702,000.00 in income taxes, reflecting an effective tax rate of 0.51.
| Income Tax | 702,000.00 |
| Effective Tax Rate | 0.51 |
Stock Price Statistics
Structure Therapeutics Inc.'s stock has declined approximately -21.02619% over the past 52 weeks. The 50-day moving average sits at 39.76, while the 200-day moving average is 51.46.
| Beta (5Y) | N/A |
| 52-Week Price Change | -21.02619% |
| 50-Day Moving Average | 39.76 |
| 200-Day Moving Average | 51.46 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -266.16M, while operating income came in at -268.06M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -268.06M |
| Pretax Income | -214.13M |
| Net Income | -214.83M |
| EBITDA | -266.16M |
| EBIT | -268.06M |
| Earnings Per Share (EPS) | -3.13 |
Balance Sheet
Structure Therapeutics Inc. holds 1.34B in cash and equivalents against 6.23M in total debt, resulting in a net debt position of -272.64M. Total book value stands at 1.35B, with working capital of 1.31B providing operational flexibility.
| Cash & Cash Equivalents | 1.34B |
| Total Debt | 6.23M |
| Net Debt | -272.64M |
| Equity (Book Value) | 1.35B |
| Book Value Per Share | 6.35 |
| Working Capital | 1.31B |
Cash Flow
Structure Therapeutics Inc. produced -220.29M in operating cash flow over the past twelve months. After subtracting -4.21M in capital expenditures, free cash flow totaled -224.50M - equivalent to -3.27 per share.
| Operating Cash Flow | -220.29M |
| Capital Expenditures | -4.21M |
| Free Cash Flow | -224.50M |
| FCF Per Share | -3.27 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.66 |
| FCF Yield | -5.87 |
Scores
Structure Therapeutics Inc. posts an Altman Z-Score of 96.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 96.52 |